371 related articles for article (PubMed ID: 12524225)
1. HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells.
Dichtl W; Dulak J; Frick M; Alber HF; Schwarzacher SP; Ares MP; Nilsson J; Pachinger O; Weidinger F
Arterioscler Thromb Vasc Biol; 2003 Jan; 23(1):58-63. PubMed ID: 12524225
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ.
Wagner AH; Schwabe O; Hecker M
Br J Pharmacol; 2002 May; 136(1):143-9. PubMed ID: 11976279
[TBL] [Abstract][Full Text] [Related]
3. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors upregulate inducible NO synthase expression and activity in vascular smooth muscle cells.
Kolyada AY; Fedtsov A; Madias NE
Hypertension; 2001 Nov; 38(5):1024-9. PubMed ID: 11711492
[TBL] [Abstract][Full Text] [Related]
4. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors increase the binding activity and nuclear level of Oct-1 in mononuclear cells.
Ortego M; Hernández AG; Bustos C; Blanco-Colio LM; Hernández-Presa MA; Tuñón J; Egido J
Eur J Pharmacol; 2002 Jul; 448(2-3):113-21. PubMed ID: 12144930
[TBL] [Abstract][Full Text] [Related]
5. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells.
Mulhaupt F; Matter CM; Kwak BR; Pelli G; Veillard NR; Burger F; Graber P; Lüscher TF; Mach F
Cardiovasc Res; 2003 Sep; 59(3):755-66. PubMed ID: 14499877
[TBL] [Abstract][Full Text] [Related]
6. HMG CoA reductase inhibitors affect the fibrinolytic system of human vascular cells in vitro: a comparative study using different statins.
Wiesbauer F; Kaun C; Zorn G; Maurer G; Huber K; Wojta J
Br J Pharmacol; 2002 Jan; 135(1):284-92. PubMed ID: 11786505
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin.
Chandrasekar B; Mummidi S; Mahimainathan L; Patel DN; Bailey SR; Imam SZ; Greene WC; Valente AJ
J Biol Chem; 2006 Jun; 281(22):15099-109. PubMed ID: 16554298
[TBL] [Abstract][Full Text] [Related]
8. Lovastatin reduces nuclear factor kappaB activation induced by C-reactive protein in human vascular endothelial cells.
Lin R; Liu J; Peng N; Yang G; Gan W; Wang W
Biol Pharm Bull; 2005 Sep; 28(9):1630-4. PubMed ID: 16141529
[TBL] [Abstract][Full Text] [Related]
9. HMG-CoA reductase inhibition reduces the proinflammatory activation of human vascular smooth muscle cells by the terminal complement factor C5b-9.
Viedt C; Shen W; Fei J; Kamimura M; Hänsch GM; Katus HA; Kreuzer J
Basic Res Cardiol; 2003 Nov; 98(6):353-61. PubMed ID: 14556080
[TBL] [Abstract][Full Text] [Related]
10. 3-hydroxy-3-methylglutaryl coenzyme A reductase-independent inhibition of CD40 expression by atorvastatin in human endothelial cells.
Wagner AH; Gebauer M; Güldenzoph B; Hecker M
Arterioscler Thromb Vasc Biol; 2002 Nov; 22(11):1784-9. PubMed ID: 12426205
[TBL] [Abstract][Full Text] [Related]
11. Inhibitors of HMG-CoA reductase sensitize human smooth muscle cells to Fas-ligand and cytokine-induced cell death.
Knapp AC; Huang J; Starling G; Kiener PA
Atherosclerosis; 2000 Sep; 152(1):217-27. PubMed ID: 10996358
[TBL] [Abstract][Full Text] [Related]
12. Atorvastatin decreases C-reactive protein-induced inflammatory response in pulmonary artery smooth muscle cells by inhibiting nuclear factor-kappaB pathway.
Li J; Li JJ; He JG; Nan JL; Guo YL; Xiong CM
Cardiovasc Ther; 2010; 28(1):8-14. PubMed ID: 20074254
[TBL] [Abstract][Full Text] [Related]
13. Statins differentially regulate vascular endothelial growth factor synthesis in endothelial and vascular smooth muscle cells.
Frick M; Dulak J; Cisowski J; Józkowicz A; Zwick R; Alber H; Dichtl W; Schwarzacher SP; Pachinger O; Weidinger F
Atherosclerosis; 2003 Oct; 170(2):229-36. PubMed ID: 14612202
[TBL] [Abstract][Full Text] [Related]
14. Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.
Kleemann R; Verschuren L; de Rooij BJ; Lindeman J; de Maat MM; Szalai AJ; Princen HM; Kooistra T
Blood; 2004 Jun; 103(11):4188-94. PubMed ID: 14976045
[TBL] [Abstract][Full Text] [Related]
15. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells.
Riessen R; Axel DI; Fenchel M; Herzog UU; Rossmann H; Karsch KR
Basic Res Cardiol; 1999 Oct; 94(5):322-32. PubMed ID: 10543307
[TBL] [Abstract][Full Text] [Related]
16. Atorvastatin sensitises vascular smooth muscle cells, but not endothelial cells, to TNF-α-induced cell death.
Giordano A; Romano S; Nappo G; Messina S; Polimeno M; Corcione N; Cali G; Ferraro P; Monaco M; Zambrano N; Romano MF
Curr Pharm Des; 2012; 18(38):6331-8. PubMed ID: 23092297
[TBL] [Abstract][Full Text] [Related]
17. Statin treatment upregulates vascular neuronal nitric oxide synthase through Akt/NF-kappaB pathway.
Nakata S; Tsutsui M; Shimokawa H; Yamashita T; Tanimoto A; Tasaki H; Ozumi K; Sabanai K; Morishita T; Suda O; Hirano H; Sasaguri Y; Nakashima Y; Yanagihara N
Arterioscler Thromb Vasc Biol; 2007 Jan; 27(1):92-8. PubMed ID: 17082483
[TBL] [Abstract][Full Text] [Related]
18. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells.
Ortego M; Bustos C; Hernández-Presa MA; Tuñón J; Díaz C; Hernández G; Egido J
Atherosclerosis; 1999 Dec; 147(2):253-61. PubMed ID: 10559511
[TBL] [Abstract][Full Text] [Related]
19. Antioxidant effects of statins via S-nitrosylation and activation of thioredoxin in endothelial cells: a novel vasculoprotective function of statins.
Haendeler J; Hoffmann J; Zeiher AM; Dimmeler S
Circulation; 2004 Aug; 110(7):856-61. PubMed ID: 15289372
[TBL] [Abstract][Full Text] [Related]
20. Statins differ in their ability to block NF-kappaB activation in human blood monocytes.
Hilgendorff A; Muth H; Parviz B; Staubitz A; Haberbosch W; Tillmanns H; Hölschermann H
Int J Clin Pharmacol Ther; 2003 Sep; 41(9):397-401. PubMed ID: 14518599
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
